Trial Profile

A Master Protocol of an Open-Label, Multi-Drug, Multi-Center, Phase II Platform Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma (GEMINI-PeriOp GC)

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 23 Aug 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Rilvegostomig (Primary) ; Sonesitatug-Vedotin (Primary) ; Capecitabine; Fluorouracil; Trastuzumab-deruxtecan
Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
Focus Adverse reactions; Therapeutic Use
Acronyms GEMINI-PeriOp GC

31 Jul 2025 Planned End Date changed from 15 Sep 2028 to 20 Sep 2028.
31 Jul 2025 Planned primary completion date changed from 18 Dec 2026 to 21 Sep 2026.
31 Jul 2025 Status changed from not yet recruiting to recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com